Detalles de la búsqueda
1.
A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases.
J Pharmacokinet Pharmacodyn
; 48(4): 525-541, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33728547
2.
Improving the evaluation of COPD exacerbation treatment effects by accounting for early treatment discontinuations: a post-hoc analysis of randomized clinical trials.
Respir Res
; 21(1): 158, 2020 Jun 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32571311
3.
Computational modeling of lung deposition of inhaled particles in chronic obstructive pulmonary disease (COPD) patients: identification of gaps in knowledge and data.
Crit Rev Toxicol
; 49(2): 160-173, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31012388
4.
A novel in vivo receptor occupancy methodology for the glucocorticoid receptor: toward an improved understanding of lung pharmacokinetic/pharmacodynamic relationships.
J Pharmacol Exp Ther
; 353(2): 279-87, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25680710
5.
Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
Br J Clin Pharmacol
; 80(6): 1362-73, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26174611
6.
Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor.
Mol Pharm
; 10(11): 4252-62, 2013 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24079718
7.
A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations.
Pharm Res
; 29(2): 574-84, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21948384
8.
A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations.
Pharm Res
; 29(3): 695-706, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21948457
9.
A stochastic mixed effects model to assess treatment effects and fluctuations in home-measured peak expiratory flow and the association with exacerbation risk in asthma.
CPT Pharmacometrics Syst Pharmacol
; 11(2): 212-224, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34797036
10.
Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers.
Drug Des Devel Ther
; 16: 485-497, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35264846
11.
Effects of ketoconazole on the in vivo biotransformation and hepatobiliary transport of the thrombin inhibitor AZD0837 in pigs.
Drug Metab Dispos
; 39(2): 239-46, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20978106
12.
Longitudinal FEV1 and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling.
Int J Chron Obstruct Pulmon Dis
; 16: 101-111, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33488073
13.
Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation.
Br J Pharmacol
; 178(22): 4440-4451, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34250588
14.
Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837.
Eur J Clin Pharmacol
; 66(9): 903-10, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20535457
15.
Estimation of Equipotent Doses for Anti-Inflammatory Effects of Prednisolone and AZD9567, an Oral Selective Nonsteroidal Glucocorticoid Receptor Modulator.
CPT Pharmacometrics Syst Pharmacol
; 9(8): 444-455, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32501650
16.
Quantification and reliability of [11C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung - a test-retest PET study in control subjects.
EJNMMI Res
; 10(1): 59, 2020 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32495011
17.
Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials.
Lancet Rheumatol
; 2(1): e31-e41, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38258274
18.
Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs.
Drug Metab Dispos
; 36(8): 1519-28, 2008 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-18458048
19.
Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Physiol Rep
; 6(5)2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29488355
20.
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Thromb Haemost
; 95(3): 447-53, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16525572